Phaseline

Companies › Laboratorios Silanes S.A. de C.V.

Laboratorios Silanes S.A. de C.V.: clinical trials, targets and expected readouts

2 active drug programs in 32 registered trials: 21 Phase 2, 5 Phase 4, 3 Phase 3, 3 Phase 1; Neurology, Immunology, Other, Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Etoricoxib
Cyclooxygenase-2 inhibitor
PTGS2Phase 3Gout Arthritis; Parkinson Disease; Orthodontic Pain (D013850)Dec 2026
Celecoxib
Cyclooxygenase-2 inhibitor
PTGS2Phase 3Joint Pain; Shoulder Arthropathy; Pain, Postoperative; Surgery …–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03825809CelecoxibPhase 2Narcotic UseOtherJan 2020
NCT05488847CelecoxibPhase 4Shoulder ArthropathyOtherDec 2024
NCT07559682EtoricoxibPhase 1Orthodontic Pain (D013850)OtherAug 2025
NCT07559682CelecoxibPhase 1Orthodontic Pain (D013850)OtherAug 2025
NCT06863636CelecoxibPhase 3Joint PainImmunologyOct 2025
NCT06863636CelecoxibPhase 3Joint PainImmunologyOct 2025
NCT02574728CelecoxibPhase 2CancerOncologyJun 2026
NCT07174570CelecoxibPhase 2Advanced Hepatocellular CarcinomaOncologyNov 2026
NCT07246278CelecoxibPhase 1Parkinson DiseaseNeurologyNov 2026
NCT05637086CelecoxibPhase 2EpilepsyNeurologyDec 2026
NCT05731726CelecoxibPhase 2pMMROncologyDec 2026
NCT06863701EtoricoxibPhase 3Gout ArthritisImmunologyDec 2026
NCT06379425CelecoxibPhase 4Pain, PostoperativeNeurologyJan 2027
NCT01344200CelecoxibPhase 2Pharmacokinetics of Celecoxib in ChildrenOtherFeb 2027
NCT05722002CelecoxibPhase 4SurgeryOtherFeb 2027
NCT07049185CelecoxibPhase 2Esophageal Squamous Cell CarcinomaOncologyMar 2027
NCT03926338CelecoxibPhase 2Colorectal CancerOncologyApr 2027
NCT05434065CelecoxibPhase 2Intracerebral HemorrhageNeurologyJul 2027
NCT07150949CelecoxibPhase 2Locally Advanced Rectal CancerOncologyAug 2027
NCT06505187CelecoxibPhase 2ParotidectomyOtherSep 2027
NCT07370532EtoricoxibPhase 2Parkinson DiseaseNeurologyNov 2027
NCT07809893CelecoxibPhase 2Colorectal CancerOncologyDec 2027
NCT07494565CelecoxibPhase 2Diffuse Large B-Cell Lymphoma (DLBCL)OncologyMar 2028
NCT06245109CelecoxibPhase 4Knee OsteoarthritisImmunologyMar 2028
NCT06903858CelecoxibPhase 2Colorectal CancerOncologyApr 2028
NCT07076069CelecoxibPhase 4Rotator Cuff RepairsOtherJun 2028
NCT07597902CelecoxibPhase 2Post-acute Sequelae of COVID-19Infectious diseaseJun 2028
NCT07154316CelecoxibPhase 2Colorectal CancerOncologyAug 2028
NCT03498326CelecoxibPhase 2Pancreatic CancerOncologyMar 2030
NCT01356290CelecoxibPhase 2Medulloblastoma RecurrentOncologyApr 2030
NCT00268476CelecoxibPhase 2Prostate CancerOncologyDec 2030
NCT03026140CelecoxibPhase 2Colon CarcinomaOncologyMar 2032

Targets

PTGS2 (2)

Companies with the same targets

ZetrOZ Sirnaomics Caribou Biosciences Sana Biotechnology Brainfarma Industria Química e Farmacêutica S/A AFT Pharmaceuticals

Companies built like this

AFT Pharmaceuticals Cartesian Therapeutics Brainfarma Industria Química e Farmacêutica S/A Epygenix Zhejiang Wenda Pharma Technology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.